Risk of severe COVID‐19 in patients treated with IBD medications: a French nationwide study
Open Access
- 10 June 2021
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (2) , 160-166
Abstract
Summary: Background: Recently, the SECURE‐IBD study, based on a physician‐reported registry, suggested that thiopurines, either alone or combined with anti‐TNF, may increase risk of severe COVID‐19.Aims: To compare the risk of severe COVID‐19 according to IBD medications in a large and unselected population.Methods: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID‐19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio‐demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities.Results: Among 268 185 IBD patients, 600 were hospitalised for COVID‐19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID‐19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66‐1.35) for immunomodulator monotherapy, 1.05 (0.80‐1.38) for anti‐TNF monotherapy, 0.80 (0.38‐1.69) for anti‐TNF combination therapy, 1.06 (0.55‐2.05) for vedolizumab and 1.25 (0.64‐2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID‐19 did not differ according to IBD treatment.Conclusions: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID‐19 infection.Keywords
This publication has 14 references indexed in Scilit:
- Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort StudyJournal of Crohn's and Colitis, 2020
- Effect of IBD medications on COVID-19 outcomes: results from an international registryGut, 2020
- Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease—A Danish Prospective Population-based Cohort StudyJournal of Crohn's and Colitis, 2020
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International MeetingGastroenterology, 2020
- Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network StudyGastroenterology, 2020
- The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitisAlimentary Pharmacology & Therapeutics, 2019
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel DiseaseJAMA, 2017
- Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in FranceRevue D'Épidémiologie Et de Santé Publique, 2017
- Therapeutic management of inflammatory bowel disease in real‐life practice in the current era of anti‐TNF agents: analysis of the French administrative health databases 2009–2014Alimentary Pharmacology & Therapeutics, 2016